{"title":"治疗的主要方式将会改变:转移性肾细胞癌的中低危患者不再需要减量肾切除术","authors":"I. Tsimafeyeu","doi":"10.36959/896/601","DOIUrl":null,"url":null,"abstract":"To date, cytoreductive nephrectomy before systemic therapy is generally recommended in patients with a potentially surgically resectable primary renal cell carcinoma (RCC) and multiple metastases. Targeted therapy with tyrosine kinase inhibitors is widely used in the firstline treatment of metastatic renal cell carcinoma. The objective of CARMENA study was to determine whether cytoreductive surgery before the initiation of the targeted therapy in patients with metastatic renal cell carcinoma (mRCC) is required.","PeriodicalId":92927,"journal":{"name":"Journal of renal cancer","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Mainstay of Treatment will be Changed: Cytoreductive Nephrectomy Would Not be Required in Intermediate and Poor Risk Patients with Metastatic Renal Cell Carcinoma Cancer\",\"authors\":\"I. Tsimafeyeu\",\"doi\":\"10.36959/896/601\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To date, cytoreductive nephrectomy before systemic therapy is generally recommended in patients with a potentially surgically resectable primary renal cell carcinoma (RCC) and multiple metastases. Targeted therapy with tyrosine kinase inhibitors is widely used in the firstline treatment of metastatic renal cell carcinoma. The objective of CARMENA study was to determine whether cytoreductive surgery before the initiation of the targeted therapy in patients with metastatic renal cell carcinoma (mRCC) is required.\",\"PeriodicalId\":92927,\"journal\":{\"name\":\"Journal of renal cancer\",\"volume\":\"62 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of renal cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36959/896/601\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of renal cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36959/896/601","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Mainstay of Treatment will be Changed: Cytoreductive Nephrectomy Would Not be Required in Intermediate and Poor Risk Patients with Metastatic Renal Cell Carcinoma Cancer
To date, cytoreductive nephrectomy before systemic therapy is generally recommended in patients with a potentially surgically resectable primary renal cell carcinoma (RCC) and multiple metastases. Targeted therapy with tyrosine kinase inhibitors is widely used in the firstline treatment of metastatic renal cell carcinoma. The objective of CARMENA study was to determine whether cytoreductive surgery before the initiation of the targeted therapy in patients with metastatic renal cell carcinoma (mRCC) is required.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
